Panaxium

What Panaxium does

Panaxium is a privately held bioelectronic medicine company developing precision neuromodulation therapy for stroke recovery and traumatic brain injury rehabilitation. The company is headquartered in Aix-en-Provence, France, with a second office in Toronto, Canada, and was founded in 2016. Its core technology is an iontronic brain-machine interface platform comprising an ultrathin temporary implant — described as thin as the diameter of a red blood cell — that gently conforms to the brain's surface and delivers stimulation targeting Cortical Layer 5. The platform is paired with a proprietary MRI protocol and AI-assisted analysis that generates patient-specific representations of functional networks, identifies injury-related disruption, predicts natural recovery trajectories, and supports implantation planning. The company also indicates optional neuron-scale drug delivery capability for combination therapies.

The intended end users are surgeons and neurologists at premier medical institutions who would deploy the device in clinical settings to treat stroke survivors and TBI patients. Panaxium has explicitly positioned itself in the preclinical stage, with first-in-human clinical investigation underway in 2023 under Dr. Gilles Huberfeld at the Rothschild Foundation Hospital in Paris, and preclinical trials ongoing at sites in Europe and North America including Queen's University/Kingston General Hospital and Université de Montréal. The business model is structured as direct enterprise hardware sales to healthcare institutions once regulatory clearance is obtained, supported by a clinical advisory and co-development network spanning University of Cambridge, UPenn, Northwestern, Columbia, UCLA, Toronto General Hospital, and others. Panaxium has received equity investment from the Ontario Brain Institute (April 2023), grant funding from the Center of Aging and Brain Health Innovation (November 2025), and earlier incubation from Incubateur Impulse (2016). The company has not yet commercialized any product and currently generates no product revenue. Strategic partners include Synaptive Medical for integrated assessment and planning capabilities.

Name

Panaxium

Legal name

Panaxium

Website

https://panaxium.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Panaxium is a preclinical bioelectronic medicine company developing an ultrathin iontronic brain-machine interface implant and AI-assisted MRI treatment planning for precision neuromodulation therapy targeting stroke recovery, intended for use by surgeons and neurologists.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Brain-machine interfaces
• Neuromodulation therapy
• Bioelectronic medicine
• Stroke recovery
• Neural implants

Headquarters

HQ city

Aix-en-provence

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

1. Neuromodulation Medical Devices: Panaxium develops and commercializes neuromodulation implants for stroke recovery. The company is in preclinical trial stage with plans to move to human clinical trials. Revenue will be generated through the sale of medical devices to healthcare institutions.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Panaxium develops an ultrathin iontronic brain-machine interface (BMI) implant combined with a proprietary AI-assisted MRI protocol to deliver precision neuromodulation therapy for stroke recovery and traumatic brain injury rehabilitation. The temporary cortical implant provides high-resolution, selective stimulation to enable the brain to remap and restore function, while the AI platform generates patient-specific functional network representations for personalized treatment planning. The company is currently in preclinical trials at world-leading sites in Europe and North America.

Product overview

Panaxium is a bioelectronic medicine company developing a precision therapy BMI (brain-machine interface) platform. The company's core offering consists of an ultrathin iontronic implant that provides unprecedented resolution and activation control for stimulating the brain's Cortical Layer 5, combined with a proprietary MRI protocol and AI-assisted analysis for patient-specific treatment planning. The neuromodulation stroke therapy is the primary therapeutic application, designed to help stroke survivors restore function through precision brain stimulation.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision Therapy BMI Platform Panaxium's integrated brain-machine interface platform built for surgeons and neurologists to directly intervene, treat brain injuries, and promote precision healing through neuromodulation. It combines an ultrathin iontronic temporary implant with a proprietary AI-assisted MRI protocol that generates patient-specific functional network representations for treatment planning.
• Ultrathin Iontronic Implant A lightweight, ultrathin temporary iontronic implant approximately the diameter of a red blood cell that gently conforms to the brain surface to provide unparalleled resolution, stimulation control, and safety for precisely targeting neural pathways (including Cortical Layer 5) during stroke recovery and traumatic brain injury rehabilitation. The device also records neural activity to adjust therapy and predict movement intent, with optional combination drug delivery.
• Neuromodulation Stroke Therapy A novel neuromodulation therapy using iontronic technology to precisely stimulate the brain and help stroke survivors restore cognitive, motor, and speech function. Designed to address the $700 billion annual societal cost of stroke and serve the more than 100 million stroke survivors globally who are otherwise left with life-altering disabilities.

Quantifiable outcome

• 9 of 10 stroke survivors left with life-altering disabilities following current recovery programs
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Synaptive MedicalcoreTechnology or IntegrationPartnership to unlock the ultimate brain-machine interface neuro-recovery therapy. The partnership focuses on the ability to assess, plan, and strategize personalized functional remapping to every patient's specific injury using Synaptive's technology alongside Panaxium's device.
• Université de MontréalcoreStrategic or Co-development PartnerProfessor Numa Dancause conducts research on premotor cortex function and cortical plasticity following brain injury. He refines the design of Panaxium's preclinical and clinical studies and conducts collaborative work using Panaxium's proprietary devices.
• University of CambridgecoreStrategic or Co-development PartnerProfessor George Malliaras serves as Principal Scientific Advisor. He focuses on the design and validation of conductive polymer devices to interface with the brain for understanding and treating neurological disorders.
• Rothschild Foundation HospitalcoreStrategic or Co-development PartnerDr. Gilles Huberfeld leads the first in-human trial of Panaxium's next-generation iontronic brain computer interface in Paris, France in 2023.
• Queen's UniversitycoreStrategic or Co-development PartnerDr. DJ Cook serves as Principal Investigator for preclinical trials. He is a neurosurgeon at Kingston General Hospital and renowned neuroscientist specializing in how the brain adapts after injury.
• UCLAminorStrategic or Co-development PartnerDr. Steven C. Cramer serves as Clinical Advisor. He is a world-renowned neurologist and Professor of Neurology, Director of Research at California Rehabilitation Institute.
• Northwestern UniversityminorStrategic or Co-development PartnerDr. Jonathan Rivnay serves as Scientific Advisor. He leads research on active materials such as conducting polymers for seamless integration with cells and tissue.
• Columbia UniversityminorStrategic or Co-development PartnerDr. Dion Khodagholy serves as Scientific Advisor. He focuses on designing novel electronic devices for efficient interaction with neural networks.
• University of PennsylvaniaminorStrategic or Co-development PartnerDr. Brian Litt serves as Clinical Advisor for Neurology & Biomedical Engineering. He focuses on translating neuro-engineering research into patient care.
• Toronto General HospitalcoreStrategic or Co-development PartnerDr. Taufik Valiante serves as advisor. He is Director of the Surgical Epilepsy Program at Krembil Neuroscience Center and Director of CRANIA.
• IONBIKE 2.0minorStrategic or Co-development PartnerPanaxium was invited to join IONBIKE 2.0, an international research exchange for short-term research and innovation collaborations across industry and academia to explore science and technology applications in bioelectronics.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Synchron: Synchron has developed a minimally invasive endovascular brain-computer interface (Stentrode) and has begun human clinical trials. Both companies are developing BMI platforms for neurological intervention, with Synchron further along clinically.
• Blackrock Neurotech: Blackrock Neurotech develops neural implant arrays and has decades of human implant experience (e.g., BrainGate). Comparable as a direct cortical implant developer, though focused more on motor BCIs and research use cases.
• Neuralink: Neuralink develops implantable brain-machine interfaces with high channel count. Both companies target direct cortical interfaces for clinical applications, though Neuralink focuses on motor restoration and BCIs for paralysis, while Panaxium focuses on stroke recovery neuromodulation.
• Precision Neuroscience: Precision Neuroscience is developing a thin-film cortical interface (Layer 7) with high electrode density. Directly comparable as a developer of ultrathin cortical electrode arrays targeting both clinical and research applications.
• Paradromics: Paradromics is developing high-data-rate neural interfaces for both medical and computational applications. Comparable as a direct peer in the implantable brain-machine interface category.

Emerging players

• MicroTransponder: MicroTransponder has FDA-approved Vivistim vagus nerve stimulation system for post-stroke rehabilitation. A direct competitor in the stroke rehabilitation neuromodulation category, though via vagus nerve rather than cortical interface.
• Motif Neurotech: Motif Neurotech is developing minimally invasive brain neuromodulation devices for mental health. Comparable as an emerging neurotechnology company targeting brain stimulation, though focused on psychiatric indications rather than stroke recovery.

Broad incumbents

• Medtronic Neuromodulation: Medtronic is a major neuromodulation incumbent with Activa DBS and other established systems. Comparable as a broad incumbent in implantable neuromodulation with extensive regulatory and commercial infrastructure.
• Abbott Neuromodulation: Abbott is a major neuromodulation incumbent with FDA-approved DBS systems and is also developing directional leads for brain stimulation. Comparable as a broad incumbent that could enter the stroke recovery indication with existing infrastructure.
• Boston Scientific Neuromodulation: Boston Scientific is an established medical device incumbent with deep neuromodulation portfolio (DBS, SCS). Comparable as a broad neuromodulation player with regulatory, manufacturing, and commercial scale that Panaxium does not yet possess.

Market position

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/panaxium

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panaxium